Companies › PT. Prodia Stem Cell Indonesia
6 active drug programs in 11 registered trials: 10 Phase 1, 1 Phase 2; Respiratory, Oncology, Neurology, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Conditioned Medium Intranasal secretome from mesenchymal stem cells | – | Phase 1 | Ischemic Stroke; Cerebral Palsy | Dec 2026 |
| UC-MSC and Secretome Umbilical cord mesenchymal stem cells combined with conditioned medium (secretome) | – | Phase 1 | Androgenetic Alopecia; Acute Respiratory Distress Syndrome | Dec 2026 |
| Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) Intraparenchymal transplantation of mesenchymal stromal cells for neurogenesis | – | Phase 1 | Ischemic Stroke; Cerebral Palsy; Diabetic Nephropathy Type 2; Chronic Obstructive Pulmonary Disease (COPD) | Dec 2026 |
| Umbilical Cord-Mesenchymal Stem Cell (UC-MSC) Mesenchymal stem cells derived from umbilical cord tissue | – | Phase 1 | Acute Respiratory Distress Syndrome | Dec 2026 |
| Allo-Dendritic Cell-Secretome (Allogeneic Dendritic Cell-Secretome) Allogeneic dendritic cell secretome therapy | – | Phase 1 | Nasopharyngeal Cancer | – |
| Auto-DC (Autologous Dendritic Cell) Autologous dendritic cell therapy | – | Phase 1 | Nasopharyngeal Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05261750 | Auto-DC (Autologous Dendritic Cell) | Phase 1 | Nasopharyngeal Cancer | Oncology | Feb 2026 |
| NCT05261750 | Allo-Dendritic Cell-Secretome (Allogeneic Dendritic Cell-Secretome) | Phase 1 | Nasopharyngeal Cancer | Oncology | Feb 2026 |
| NCT05008588 | Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) | Phase 1 | Ischemic Stroke | Neurology | Mar 2026 |
| NCT05008588 | Conditioned Medium | Phase 1 | Ischemic Stroke | Neurology | Mar 2026 |
| NCT07429253 | UC-MSC and Secretome | Phase 1 | Androgenetic Alopecia | Immunology | Jun 2026 |
| NCT07439848 | Umbilical Cord-Mesenchymal Stem Cell (UC-MSC) | Phase 1 | Acute Respiratory Distress Syndrome | Respiratory | Dec 2026 |
| NCT07439848 | UC-MSC and Secretome | Phase 1 | Acute Respiratory Distress Syndrome | Respiratory | Dec 2026 |
| NCT04314687 | Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) | Phase 1 | Cerebral Palsy | Neurology | Dec 2026 |
| NCT04314687 | Conditioned Medium | Phase 1 | Cerebral Palsy | Neurology | Dec 2026 |
| NCT07396155 | Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) | Phase 1 | Diabetic Nephropathy Type 2 | Genitourinary | Jul 2027 |
| NCT07441226 | Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | Respiratory | Dec 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.